Liraglutide hospital discharge trial : A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge
Abstract Aim To compare a glucagon‐like peptide‐1 receptor agonist with basal insulin at hospital discharge in patients with uncontrolled type 2 diabetes in a randomized clinical trial. Methods A total of 273 patients with glycated haemoglobin (HbA1c) 7%–10% (53–86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge. The primary endpoint was difference in HbA1c at 12 and 26 weeks. Secondary endpoints included hypoglycaemia, changes in body weight, and achievement of HbA1c <7% (53 mmol/mol) without hypoglycaemia or weight gain. Results The between‐group difference in HbA1c at 12 weeks and 26 weeks was −0.28% (95% CI −0.64, 0.09), and at 26 weeks it was −0.55%, (95% CI −1.01, −0.09) in favour of liraglutide. Liraglutide treatment resulted in a lower frequency of hypoglycaemia <3.9 mmol/L (13% vs 23%; P= 0.04), but there was no difference in the rate of clinically significant hypoglycaemia <3.0 mmol/L. Compared to insulin glargine, liraglutide treatment was associated with greater weight loss at 26 weeks (−4.7 ± 7.7 kg vs −0.6 ± 11.5 kg; P < 0.001), and the proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia was 48% versus 33% ( P= 0.05) at 12 weeks and 45% versus 33% ( P= 0.14) at 26 weeks in liraglutide versus insulin glargine. The proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia and no weight gain was higher with liraglutide at 12 (41% vs 24%, P= 0.005) and 26 weeks (39% vs 22%; P= 0.014). The incidence of gastrointestinal adverse events was higher with liraglutide than with insulin glargine ( P < 0.001). Conclusion Compared to insulin glargine, treatment with liraglutide at hospital discharge resulted in better glycaemic control and greater weight loss, but increased gastrointestinal adverse events..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Diabetes, Obesity and Metabolism - 23(2021), 6, Seite 1351-1360 |
| Beteiligte Personen: |
Pasquel, Francisco J. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 John Wiley & Sons Ltd |
|---|
| Umfang: |
10 |
|---|
| doi: |
10.1111/dom.14347 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY004635434 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY004635434 | ||
| 003 | DE-627 | ||
| 005 | 20230307140504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230214s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/dom.14347 |2 doi | |
| 028 | 5 | 2 | |a DOM_DOM14347.xml |
| 035 | |a (DE-627)WLY004635434 | ||
| 035 | |a (WILEY)DOM14347 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.76 |2 bkl | ||
| 084 | |a 44.89 |2 bkl | ||
| 100 | 1 | |a Pasquel, Francisco J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Liraglutide hospital discharge trial |b A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge |
| 264 | 1 | |c 2021 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 John Wiley & Sons Ltd | ||
| 520 | |a Abstract Aim To compare a glucagon‐like peptide‐1 receptor agonist with basal insulin at hospital discharge in patients with uncontrolled type 2 diabetes in a randomized clinical trial. Methods A total of 273 patients with glycated haemoglobin (HbA1c) 7%–10% (53–86 mol/mol) were randomized to liraglutide (n = 136) or insulin glargine (n = 137) at hospital discharge. The primary endpoint was difference in HbA1c at 12 and 26 weeks. Secondary endpoints included hypoglycaemia, changes in body weight, and achievement of HbA1c <7% (53 mmol/mol) without hypoglycaemia or weight gain. Results The between‐group difference in HbA1c at 12 weeks and 26 weeks was −0.28% (95% CI −0.64, 0.09), and at 26 weeks it was −0.55%, (95% CI −1.01, −0.09) in favour of liraglutide. Liraglutide treatment resulted in a lower frequency of hypoglycaemia <3.9 mmol/L (13% vs 23%; P= 0.04), but there was no difference in the rate of clinically significant hypoglycaemia <3.0 mmol/L. Compared to insulin glargine, liraglutide treatment was associated with greater weight loss at 26 weeks (−4.7 ± 7.7 kg vs −0.6 ± 11.5 kg; P < 0.001), and the proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia was 48% versus 33% ( P= 0.05) at 12 weeks and 45% versus 33% ( P= 0.14) at 26 weeks in liraglutide versus insulin glargine. The proportion of patients with HbA1c <7% (53 mmol/mol) without hypoglycaemia and no weight gain was higher with liraglutide at 12 (41% vs 24%, P= 0.005) and 26 weeks (39% vs 22%; P= 0.014). The incidence of gastrointestinal adverse events was higher with liraglutide than with insulin glargine ( P < 0.001). Conclusion Compared to insulin glargine, treatment with liraglutide at hospital discharge resulted in better glycaemic control and greater weight loss, but increased gastrointestinal adverse events. | ||
| 700 | 1 | |a Urrutia, Maria A. |4 aut | |
| 700 | 1 | |a Cardona, Saumeth |4 aut | |
| 700 | 1 | |a Coronado, Karla W. Z. |4 aut | |
| 700 | 1 | |a Albury, Bonnie |4 aut | |
| 700 | 1 | |a Perez‐Guzman, Mireya C. |4 aut | |
| 700 | 1 | |a Galindo, Rodolfo J. |4 aut | |
| 700 | 1 | |a Chaudhuri, Ajay |4 aut | |
| 700 | 1 | |a Iacobellis, Gianluca |4 aut | |
| 700 | 1 | |a Palacios, Juan |4 aut | |
| 700 | 1 | |a Farias, Javier M. |4 aut | |
| 700 | 1 | |a Gomez, Patricia |4 aut | |
| 700 | 1 | |a Anzola, Isabel |4 aut | |
| 700 | 1 | |a Vellanki, Priyathama |4 aut | |
| 700 | 1 | |a Fayfman, Maya |4 aut | |
| 700 | 1 | |a Davis, Georgia M. |4 aut | |
| 700 | 1 | |a Migdal, Alexandra L. |4 aut | |
| 700 | 1 | |a Peng, Limin |4 aut | |
| 700 | 1 | |a Umpierrez, Guillermo E. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes, Obesity and Metabolism |g 23(2021), 6, Seite 1351-1360 |w (DE-627)WLY004624327 |x 14631326 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2021 |g number:6 |g pages:1351-1360 |g extent:10 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.76 |q ASE |
| 936 | b | k | |a 44.89 |q ASE |
| 951 | |a AR | ||
| 952 | |d 23 |j 2021 |e 6 |h 1351-1360 |g 10 | ||